These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9537217)

  • 1. Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm.
    Singh BN
    Am J Cardiol; 1998 Mar; 81(6A):3D-13D. PubMed ID: 9537217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling cardiac arrhythmias: an overview with a historical perspective.
    Singh BN
    Am J Cardiol; 1997 Oct; 80(8A):4G-15G. PubMed ID: 9354407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What niche will newer class III antiarrhythmic drugs occupy?
    Singh BN; Sarma JS
    Curr Cardiol Rep; 2001 Jul; 3(4):314-23. PubMed ID: 11406090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
    Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR
    Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular and ionic specificity of antiarrhythmic drug actions.
    Nattel S
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):272-82. PubMed ID: 10090234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
    Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J
    Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic drugs: present and future.
    Sharma S
    J Assoc Physicians India; 2007 Apr; 55 Suppl():43-6. PubMed ID: 18368867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and new drugs for the treatment of arrhythmias.
    Auer J; Berent R; Weber T; Lassnig E; Eber B
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1029-36. PubMed ID: 12186263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
    Singh BN
    Am J Cardiol; 1990 Sep; 66(9):9C-20C. PubMed ID: 1699400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.